IMNM
Immunome Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Immunome Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
No other changes.
No other changes.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
+6.63%
vs ±18.3% implied · ×0.36
shaded = implied · ▲▼ = realized
Immunome Inc.
20.31
0.00 · +0.01%
post 19.52 −3.90%
| Manager | Value | % base | |
|---|---|---|---|
| T. Rowe Price | $417.0M | 16.61% | +20.24% |
| FMR | $360.0M | 14.34% | +0.10% |
| BlackRockindex-like | $186.6M | 7.43% | +7.80% |
| State Streetindex-like | $116.4M | 4.64% | +1.75% |
| Wellington | $110.4M | 4.40% | +10.11% |
| Manager | Value | % base | |
|---|---|---|---|
| T. Rowe Price | $417.0M | 16.61% | +20.24% |
| FMR | $360.0M | 14.34% | +0.10% |
| BlackRockindex-like | $186.6M | 7.43% | +7.80% |
| State Streetindex-like | $116.4M | 4.64% | +1.75% |
| Wellington | $110.4M | 4.40% | +10.11% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Immunome Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Immunome Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
Linked news
Bull3
Bear1
Expected move
Inputs8Q avg ±4.3%·×4.59·rich
straddle ±21.3%
spot 19.52exp Nov 20ATM strike 20ATM straddle 4.90IV 149%